Sunscreen containing phenyldibenzoimidazole tetrasulfonate disodium and terephthalylidene dicamphor sulfonic acid

Abstract

a) Triethanolamine salt of disodium phenyl dibenzimidazole tetrasulfonate (INCI), and b) Triethanolamine salt of terephthalylidene dicamphor sulfonic acid (INCI).

Description

Technical Field

[0001] The present invention relates to a cosmetic preparation containing the triethanolamine salt of disodium phenyl dibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) and the triethanolamine salt of terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid).

[0002] The trend from a refined bluish-white color to a "healthy and sporty brown skin" has continued for many years. To achieve this, people expose their skin to sunlight because sunlight induces pigment formation in the form of melanin formation. However, the ultraviolet rays of sunlight also cause damage to the skin. When overexposed to light in the UVB region (wavelength: 280 - 320 nm), in addition to acute damage (sunburn), long-term damage such as an increased risk of developing skin cancer occurs. Furthermore, the excessive effects of UVB rays and UVA rays (wavelength: 320 - 400 nm) lead to the weakening of the elastic fibers and collagen fibers of the connective tissue. This results in numerous phototoxic reactions and photoallergy reactions, causing skin aging earlier than expected.

[0003] Therefore, to protect the skin, many light protection filter substances that can be used in cosmetic preparations have been developed. These UVA filters and UVB filters are summarized in the form of a positive list such as Annex 7 of the cosmetic regulations in most developed countries.

[0004] Although there are many commercially available sunscreens, it must not be hidden that these preparations of the prior art have some drawbacks.

[0005] Over the years, the demand for UV-A filtering substances has been steadily increasing. This is particularly due to the numerous government regulations that require a sufficient ratio of UV-A protection to UV-B protection in sunscreens. However, the number of UV-A filters available for use in cosmetics is extremely limited. Basically, oil-soluble compounds such as butyl methoxydibenzoylmethane or diethylamino hydroxybenzoylhexyl benzoate are used.

[0006] However, to achieve particularly high UV protection, a UV-A filter also needs to be incorporated into the aqueous phase. For these purposes, around 2000, Symrise developed disodium phenyl dibenzimidazole tetrasulfonate (INCI), a compound used as a water-soluble UV-A filter. However, this substance has the drawback of strongly fluorescing in a specific wavelength range. This effect was first observed by attendees in discos, where they glowed bluish under "black light." This fluorescence phenomenon initially rendered the UV filter unsuitable for further use in cosmetics, and numerous research projects were launched to solve this problem. Symrise found the first promising solution using troxerutine. This solution was successfully patented in European Patent No. 2185126.

[0007] Although the combination with troxerutine resulted in a significant attenuation of fluorescence, a weak residual fluorescence still remained, further hindering the use of phenyldibenzimidazole tetrasulfonate disodium in cosmetics. Furthermore, considering the cost of such preparations and their suitability (allergic reactions cannot be ruled out in individual cases), there are reasons to avoid troxerutine.

[0008] Therefore, the object of the present invention was to solve this problem of the prior art and to further reduce the fluorescence of disodium phenyl dibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) in cosmetic preparations without the need to use troxerutin or by reducing the amount used.

[0009] Surprisingly, this challenge is a) Triethanolamine salt of disodium phenyl dibenzimidazole tetrasulfonate (INCI), b) Triethanolamine salt of terephthalylidene dicamphor sulfonic acid (INCI). This is resolved by cosmetic preparations containing [the specified ingredient].

[0010] Certainly, those skilled in the art are familiar with European Patent No. 2185126. Furthermore, there is German Patent Application No. 102022203499.6, which had not yet been published at the time of this application, but these documents could not demonstrate the path to the present invention.

[0011] According to the present invention, it is advantageous for the preparation according to the present invention to contain disodium phenyl dibenzimidazole tetrasulfonate (INCI) at a concentration of 0.1 to 5% by weight based on the total weight of the preparation. Here, according to the present invention, a content of 0.5 to 3% by weight based on the total weight of the preparation is preferred.

[0012] This compound is neutralized with triethanolamine during the preparation process.

[0013] Furthermore, an embodiment of the present invention that is more advantageous is characterized in that the preparation contains terephthalylidene dicamphor sulfonic acid (INCI) at a concentration of 0.1 to 3% by weight based on the total weight of the preparation. Here, according to the present invention, a content of 1 to 3% by weight based on the total weight of the preparation is preferred.

[0014] This sulfonic acid is similarly neutralized with triethanolamine during the preparation process.

[0015] Furthermore, in the context of the present invention, it is advantageous for the weight ratio of disodium phenyl dibenzimidazole tetrasulfonate (INCI) to terephthalylidene dicamphor sulfonic acid (INCI) to be 0:3 to 1:1.

[0016] According to the present invention, it is advantageous that the preparation according to the present invention exists in the form of an aqueous gel or an aqueous alcoholic gel.

[0017] If the product is an aqueous gel, the aqueous phase of neutralized phenyldibenzimidazole disodium tetrasulfonate is incorporated into the aqueous phase of neutralized terephthalylidene dicamphor sulfonic acid (INCI). In other words, two aqueous partial phases, each containing a sulfonic acid, are prepared, neutralized separately with triethanolamine, and then combined to form an aqueous preparation.

[0018] An advantageous embodiment of the present invention is characterized in that the preparation does not contain 2-ethylhexyl-2-cyano-3,3-diphenylacrylate (octocrylene), homomenthyl salicylate (homosalate), 4-methoxycinnamate (2-ethylhexyl) ester, 3-(4-methylbenzylidene) camphor, 2-hydroxy-4-methoxybenzophenone (oxybenzone), methyl anthralinate (INCI: Methyl Anthraliate), and sulfisobenzone (INCI: Benzophenon-4).

[0019] Furthermore, according to the present invention, it is advantageous that the preparation according to the present invention does not contain polyethylene glycol, polyethylene glycol ether, and polyethylene glycol ester (so-called PEG derivatives), nor does it contain polyacrylate, mineral oil, or silicone oil, and also does not contain parabens, methylisothiazolinone, chloromethylisothiazolinone, or DMDM ​​hydantoin.

[0020] In the cosmetic preparation or method according to the present invention, it is particularly advantageous if the preparation contains 2-phenylbenzimidazole-5-sulfonate.

[0021] In such cases, a preferred embodiment of the present invention is characterized in that the preparation contains 2-phenylbenzimidazole-5-sulfonate at a concentration of 0.1 to 8% by weight based on the total weight of the preparation.

[0022] Furthermore, according to the present invention, it is advantageous to use a sodium salt or a triethanolamine salt as the 2-phenylbenzimidazole-5-sulfonate.

[0023] According to the present invention, it is advantageous for the preparation to contain one or more compounds selected from the group consisting of xanthan gum (INCI: Xanthan Gum), welan gum (INCI: Welan Gum), gellan gum (INCI: Gelan Gum), sclerotium gum (INCI: Scerotium Gum), cellulose, and / or cellulose derivatives. Advantageous cellulose and cellulose derivatives include, for example, microcrystalline cellulose, ethyl cellulose, propyl cellulose, hydroxypropyl cellulose, methoxyethyl cellulose, methoxypropyl cellulose, and carboxymethyl cellulose.

[0024] Furthermore, according to the present invention, it is particularly advantageous for the preparation according to the present invention to contain ethylhexyl glycerin and / or 4-hydroxyacetophenone.

[0025] When the preparation according to the present invention contains only ethylhexyl glycerin and does not contain 4-hydroxyacetophenone, the advantageous use concentration according to the present invention is 0.1 to 0.5% by weight based on the total weight of the preparation.

[0026] When the preparation according to the present invention contains only 4-hydroxyacetophenone and does not contain ethylhexyl glycerin, the advantageous use concentration according to the present invention is 0.1 to 0.6% by weight based on the total weight of the preparation.

[0027] When the preparation according to the present invention contains both ethylhexyl glycerin and 4-hydroxyacetophenone, the advantageous use concentrations according to the present invention are 0.1 to 0.5% by weight for ethylhexyl glycerin and 0.1 to 0.6% by weight for 4-hydroxyacetophenone, respectively, based on the total weight of the preparation.

[0028] Furthermore, according to the present invention, it is advantageous for the preparation to contain silica and / or glass beads having a particle size of 5 to 120 μm.

[0029] Furthermore, according to the present invention, when the preparation according to the present invention contains a lipophilic phase, it is advantageous for the preparation or method that the preparation contains hexyl 2-(4'-(diethylamino)-2'-hydroxybenzoyl)benzoate, 2,4,6-tris-[anilino-(p-carbo-2'-ethyl-1'-hexyloxy)]-1,3,5-triazine (INCI: Ethylhexyl Triazone), and / or 2,4-bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: Bis-Ethylhexyloxyphenol methoxyphenyl Triazine).

[0030] Furthermore, in such cases, according to the present invention, it is advantageous for the preparation or method that the preparation contains 2,4,6-tribiphenyl-4-yl-1,3,5-triazine (INCI: Tris-Biphenyl Triazine), 2-ethoxyethyl-(2Z)-2-cyano-2-[3-(3-methoxypropylamino)cyclohex-2-en-1-ylidene]acetate (INCI: Methoxypropylamino Cyclohexylidene Ethoxyethylcyanoacetate), and / or the compound: [Chemical formula] characterized by containing the following.

[0031] Furthermore, in such cases, according to the present invention, it is advantageous for the preparation to contain lauryl glucoside and / or decyl glucoside.

[0032] An advantageous embodiment of the present invention is characterized in that the preparation contains one or more compounds selected from the group consisting of alpha-lipoic acid, folic acid, phytoene, D-biotin, coenzyme Q10, alpha-glucosylrutin, carnitine, carnosine, natural and / or synthetic isoflavonoids, flavonoids, creatine, creatinine, taurine, β-alanine, panthenol, magnolol, honokiol, tocopheryl acetate, dihydroxyacetone, 8-hexadecene-1,16-dicarboxylic acid, glycerylglycose, (2-hydroxyethyl)urea, vitamin E or its derivatives, hyaluronic acid and / or its salts, and / or compounds of licochalcone A.

[0033] According to the present invention, it is advantageous for the preparation to contain one or more alkanediols from the group of compounds of 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol, 1,2-decanediol, and 2-methyl-1,3-propanediol. Herein, according to the present invention, the use of 1,2-hexanediol is preferred.

[0034] Furthermore, in the context of the present invention, the preparations according to the present invention include limonene, citral, linalool, alpha-isomethyl ionone, geraniol, citronellol, 2-isobutyl-4-hydroxy-4-methyltetrahydropyran, 2-tert-pentylcyclohexyl acetate, 3-methyl-5-phenyl-1-pentanol, 7-acetyl-1,1,3,4,4,6-hexamethyltetralin, alpha-amyl cinnamaldehyde, alpha-methyl ionone, amyl C-butylphenyl methylpropional cinnamal, amyl salicylate, amyl cinnamyl alcohol, anise alcohol, benzoin, benzyl alcohol, benzyl benzoate, benzyl cinnamate, benzyl salicylate, bergamot oil, bitter orange oil, butylphenyl It is advantageous to contain one or more fragrance substances selected from the group of compounds of tylpropional, cardamom oil, cedrol, cinnamal, cinnamyl alcohol, citronellyl methyl crotonate, citron oil (Citronenoel), coumarin, diethyl succinate, ethyl linalool, eugenol, Ebernia furfrasea extract, Ebernia prunastri extract, farnesol, guaiac wood oil, hexyl cinnamal, hexyl salicylate, hydroxycitronellal, lavender oil, lemon oil, linalyl acetate, mandarin oil, menthyl PCA, methylheptenone, nutmeg oil, rosemary oil, sweet orange oil, terpineol, tonka bean oil, triethyl citrate, and / or vanillin.

[0035] Advantageously, according to the present invention, the preparations according to the present invention contain a film-forming agent. In the sense of the present invention, a film-forming agent is a substance of various compositions characterized by the following properties: when the film-forming agent is dissolved in water or another suitable solvent and then applied to the skin, the film-forming agent forms a film after the evaporation of the solvent, and this film essentially serves to fix the light filter on the skin and increase the water resistance of the product.

[0036] These film-forming agents can be selected from, for example, a group of polymers based on polyvinylpyrrolidone (PVP), or polyvinylpyrrolidone copolymers, such as PVP hexadecene copolymer and PVP eicocene copolymer, which are available from GAF Chemicals Cooperation under the trademark names Antaron V216 and Antaron V220.

[0037] However, according to the present invention, it is preferable that corn starch, malodextrin, and / or pullulan be used for this purpose.

[0038] In particular, the preparation and method according to the present invention are characterized in that the preparation does not contain troxerutin.

[0039] Official Exam The following formulations were prepared and their fluorescence properties were investigated: [Table 1]

[0040] The fluorescence (color intensity at 365 nm and 312 nm) was determined as follows: First, transfer 3.0 mL of the sample to a glass petri dish (5 cm in diameter). Then, place each petri dish individually on a dark base. Mount a standard DSLR or DSLM camera at a height of 30 cm (here, a Canon PowerShot SX540 HS). Mount a UV lamp in the same way (here, a VL-6.LM365 / 312 2x6W UV lamp 230V EU; set to 365 nm or 312 nm). The images in these examples were created with the following camera settings and serve only as a guideline: ISO 400, F=4.0, self-timer 25 seconds. Evaluate the images using a program that can separate the color channels. In this example, GIMP 2.10.28 was used. The color channels of the image can be separated into RGB colors using a histogram. The evaluation area of ​​the image must be appropriately selected so that only the contents of the petri dish are separated in the histogram. Values ​​for fluorescence are determined based on the blue value at excitation wavelengths of 365 nm or 312 nm.

[0041] Conclusion: Fluorescence and blue color values ​​are reduced by the presence of terephthalylidene dicamphor sulfonic acid and triethanolamine.

[0042] Examples The following examples are intended to clarify the present invention and not to limit it. Unless otherwise specified, all quantity indications, proportions, and percentages are based on the weight and total amount or gross weight of the preparation.

[0043] [Table 2]

Claims

1. a) Triethanolamine salt of disodium phenyl dibenzimidazole tetrasulfonate (INCI), b) Triethanolamine salt of terephthalylidene dicamphor sulfonic acid (INCI) A cosmetic preparation containing the following:

2. The cosmetic preparation according to claim 1, characterized in that the preparation contains disodium phenyl dibenzimidazole tetrasulfonate (INCI) at a concentration of 0.1 to 5% by weight based on the total weight of the preparation.

3. The cosmetic preparation according to claim 1 or 2, characterized in that the preparation contains terephthalylidene dicamphor sulfonic acid (INCI) at a concentration of 0.1 to 3% by weight based on the total weight of the preparation.

4. A cosmetic preparation according to any one of claims 1 to 3, characterized in that the weight ratio of disodium phenyl dibenzimidazole tetrasulfonate (INCI) to terephthalylidene dicamphor sulfonic acid (INCI) is 0:3 to 1:

1.

5. The cosmetic preparation according to any one of claims 1 to 4, characterized in that the preparation exists in the form of an aqueous gel or an aqueous alcohol gel.

6. A method for producing an aqueous cosmetic gel according to any one of claims 1 to 5, characterized in that the terephthalylidene dicamphor sulfonic acid (INCI) in a first aqueous phase is neutralized with triethanolamine, and then combined with a second aqueous phase, which is prepared separately, in which disodium phenyldibenzimidazole tetrasulfonate is neutralized with triethanolamine.

7. A cosmetic preparation or method according to any one of claims 1 to 6, characterized in that the preparation does not contain 2-ethylhexyl-2-cyano-3,3-diphenyl acrylate (octocrylene), homomenthyl salicylate (homosalate), 4-methoxycinnamate (2-ethylhexyl) ester, 3-(4-methylbenzylidene) camphor, 2-hydroxy-4-methoxybenzophenone (oxybenzone), methyl anthralinate (INCI: Methyl Anthraliate), and sulisobenzone (INCI: Benzophenon-4).

8. The cosmetic preparation or method according to any one of claims 1 to 7, characterized in that the preparation does not contain polyethylene glycol, polyethylene glycol ether, and polyethylene glycol ester (so-called PEG derivatives), nor does it contain polyacrylate, mineral oil, and silicone oil, nor does it contain parabens, methylisothiazolinone, chloromethylisothiazolinone, and DMDM ​​hydantoin.

9. The cosmetic preparation or method according to any one of claims 1 to 8, characterized in that the preparation contains 2-phenylbenzimidazole-5-sulfonate.

10. The cosmetic preparation or method according to claim 9, characterized in that the preparation contains 2-phenylbenzimidazole-5-sulfonate at a concentration of 0.1 to 8% by weight based on the total weight of the preparation.

11. The cosmetic preparation or method according to claim 10, characterized in that a sodium salt or the triethanolamine salt is used as 2-phenylbenzimidazole-5-sulfonate.

12. The cosmetic preparation or method according to any one of claims 1 to 11, characterized in that the preparation contains one or more compounds selected from the group consisting of xanthan gum (INCI), welan gum (INCI), gelan gum (INCI), scerotium gum (INCI), cellulose, and / or cellulose derivatives.

13. The cosmetic preparation or method according to any one of claims 1 to 12, characterized in that the preparation contains ethylhexylglycerin and / or 4-hydroxyacetophenone.

14. The cosmetic preparation or method according to any one of claims 1 to 13, characterized in that the preparation contains silica and / or glass beads having a particle size of 5 to 120 μm.

15. The cosmetic preparation or method according to any one of claims 1 to 14, characterized in that the preparation contains corn starch, malodextrin, and / or pullulan.

16. The cosmetic preparation or method according to any one of claims 1 to 15, characterized in that the preparation does not contain troxertine.

Images